I have high hopes for the Phase 2/3 STRIKE study.
All patients will be starting on the optimum 10mg dose and a new liquid formulation is currently in development for those with Bulbar MND who may experience greater difficulty in swallowing. Let's hope Dr Carol Worth is making significant progress on this important formulation which would add value to the enterprise.
If the Interim 24 week results of the larger STRIKE trial are equivalent to the Phase 1, then it is guaranteed that the placebo group will be fast tracked to switch to the active group.
Extraordinary data!
I have high hopes for the Phase 2/3 STRIKE study.All patients...
-
- There are more pages in this discussion • 172 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $97.22M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 20.0¢ | 19.5¢ | $244.3K | 1.244M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100000 | 19.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 257206 | 7 |
View Market Depth
| Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
| PAA (ASX) Chart |